Summary

Immunoglobulins Market Size, Share, and Analysis, By Product Type (IgG, IgA, IgM, IgD, IgE, and Others), By Route of Administration (Intravenous (IVIG), Subcutaneous (SCIg), and Others), By Application (Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), Multifocal Motor Neuropathy (MMN), Primary Immunodeficiency Disease (PID), Secondary Immunodeficiency Disease (SID), Guillain-Barre syndrome, Immune thrombocytopenic purpura (ITP), and Others), By Region (North America, Europe, Asia-Pacific, and Rest of the World), And Regional Forecast 2024-2034

PRODUCT OVERVIEW
Immunoglobulins Market is projected to exhibit a Compound Annual Growth Rate (CAGR) of 7.1% during the forecast span from 2024 to 2034. In 2023, the market size was assessed at USD 16.3 billion and is projected to reach USD 34.7 billion by the completion of 2034.
Immunoglobulins, are antibodies, which are specialized proteins produced through the immune system to discover and neutralize pathogens together with bacteria, viruses, and toxins. They are important for immune protection and are discovered in blood and different physical fluids. There are five most important forms of immunoglobulins, which include IgG, IgA, IgM, IgE, and IgD, every with wonderful roles. IgG is the maximum considerable and presents long-time period safety through remembering preceding infections. IgA protects mucosal surfaces, like the ones withinside the breathing and gastrointestinal tracts. IgM is the primary responder to infections, whilst IgE is concerned in allergic reactions. IgD performs a position in immune machine regulation. Thus, therapeutically, immunoglobulins are used in treatments for various immune disorders and infections.

MARKET HIGHLIGHTS
Immunoglobulins Market is expected to reach USD 34.7 billion during the forecast period, driven by the increasing prevalence of immune disorders, a growing geriatric population, and advancements in antibody treatments. Innovations in manufacturing technologies, such as recombinant DNA technology, and the development of more targeted and effective therapies are further propelling market growth. However, challenges include the high cost of immunoglobulin therapies, which can limit accessibility, especially in low- and middle-income countries. Additionally, concerns about product safety and quality, regulatory hurdles, and complex approval processes pose challenges. Supply chain disruptions and shortages can also impact availability. Despite these challenges, ongoing research and development and increasing healthcare investments are expected to drive continued growth in the immunoglobulins market.
Immunoglobulins Market Segments:

• By Product Type
o IgG
o IgA
o IgM
o IgD
o IgE
o Others
• By Route of Administration
o Intravenous (IVIG)
o Subcutaneous (SCIg)
o Others
• By Application
o Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
o Multifocal Motor Neuropathy (MMN)
o Primary Immunodeficiency Disease (PID)
o Secondary Immunodeficiency Disease (SID)
o Guillain-Barre syndrome
o Immune thrombocytopenic purpura (ITP)
o Others

MARKET DYNAMICS
Growth Drivers
Increasing prevalence of immune disorders and autoimmune diseases is Expected to Foster Market Expansion
Rising awareness and diagnosis of immune-related conditions is Anticipated to Stimulate Market Growth
Restraint
High Cost of Immunoglobulin Therapies Can Limit the Growth of the Immunoglobulins Market

Key Players
• Grifols
• CSL Behring
• Takeda Pharmaceutical Company
• Octapharma AG
• BioProduct Laboratory Ltd.
• Kedrion Biopharma
• AbbVie Inc.
• Sanofi
• Emergent BioSolutions
• Polygel Laboratories
• LFB Group
• Shanghai RAAS Blood Products Co., Ltd.
• Hualan Biological Engineering Inc.
• BPL (British Plasma Laboratories)
• Radius Health
• Other Prominent Players (Company Overview, Business Strategy, Key Product Offerings, Financial Performance, Key Performance Indicators, Risk Analysis, Recent Development, Regional Presence, SWOT Analysis)


Global Laboratory Temperature Control Units Market is further segmented by region into:
• North America Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAG.R – United States and Canada
• Latin America Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR – Mexico, Argentina, Brazil and Rest of Latin America
• Europe Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR – United Kingdom, France, Germany, Italy, Spain, Belgium, Hungary, Luxembourg, Netherlands, Poland, NORDIC, Russia, Turkey and Rest of Europe
• Asia Pacific Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR – India, China, South Korea, Japan, Malaysia, Indonesia, New Zealand, Australia and Rest of APAC
• Middle East and Africa Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR – North Africa, Israel, GCC, South Africa and Rest of MENA


Reasons to Purchase this Report
• Qualitative and quantitative analysis of the market based on segmentation involving both economic as well as non-economic factors
• Provision of market value (USD Billion) data for each segment and sub-segment
• Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market
• Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region
• Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled
• Extensive company profiles comprising of company overview, company insights, product benchmarking, and SWOT analysis for the major market players
• The current as well as the future market outlook of the industry with respect to recent developments which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions
• Includes in-depth analysis of the market of various perspectives through Porter’s five forces analysis
• Provides insight into the market through Value Chain
• Market dynamics scenario, along with growth opportunities of the market in the years to come
• 3-month post-sales analyst support.

ページTOPに戻る

Table of Contents

1.Executive Summary
1.1. Regional Market Share
1.2.Business Trends
1.3. Immunoglobulins Market: COVID-19 Outbreak
1.4. Regional Trends
1.5. Segmentation Snapshot
2. Research Methodology
2.1.Research Objective
2.2. Research Approach
2.3. Data Sourcing and Methodology
2.4.Primary Research
2.5.Secondary Research
2.5.1.Paid Sources
2.5.2. Public Sources
2.6. Market Size Estimation and Data Triangulation
3. Market Characteristics
3.1.Market Definition
3.2.Immunoglobulins Market: COVID-19 Impact
3.3. Key Segmentations
3.4.Key Developments
3.5.Allied Industry Data
4.Immunoglobulins Market – Industry Insights
4.1. Industry Segmentation
4.2.COVID-19 overview of world economy
4.3.Industry Ecosystem Channel Analysis
4.4.Innovation & Sustainability
5. Macroeconomic Indicators
6. Recent Developments
7. Market Dynamics
7.1.Introduction
7.2. Growth Drivers
7.3. Market Opportunities
7.4.Market Restraints
7.5. Market Trends
8.Risk Analysis
9. Market Analysis
9.1.Porter's Five Forces
9.2. PEST Analysis
9.2.1.Political
9.2.2. Economic
9.2.3. Social
9.2.4. Technological
10.Immunoglobulins Market
10.1.Overview
10.2. Historical Analysis (2019-2022)
10.2.1. Market Size, Y-o-Y Growth (%) and Market Forecast
11. Immunoglobulins Market Size & Forecast 2024A-2034F
11.1. Overview
11.2.Key Findings
11.3.Market Segmentation
11.3.1. By Product Type
11.3.1.1. IgG
11.3.1.1.1.By Value (USD Million) 2024-2034F
11.3.1.1.2. Market Share (%) 2024-2034F
11.3.1.1.3. Y-o-Y Growth (%) 2024-2034F
11.3.1.2.IgA
11.3.1.2.1. By Value (USD Million) 2024-2034F
11.3.1.2.2.Market Share (%) 2024-2034F
11.3.1.2.3.Y-o-Y Growth (%) 2024-2034F
11.3.1.3.IgM
11.3.1.3.1. By Value (USD Million) 2024-2034F
11.3.1.3.2.Market Share (%) 2024-2034F
11.3.1.3.3.Y-o-Y Growth (%) 2024-2034F
11.3.1.4.IgD
11.3.1.4.1. By Value (USD Million) 2024-2034F
11.3.1.4.2.Market Share (%) 2024-2034F
11.3.1.4.3.Y-o-Y Growth (%) 2024-2034F
11.3.1.5.IgE
11.3.1.5.1. By Value (USD Million) 2024-2034F
11.3.1.5.2.Market Share (%) 2024-2034F
11.3.1.5.3.Y-o-Y Growth (%) 2024-2034F
11.3.1.6.Others
11.3.1.6.1. By Value (USD Million) 2024-2034F
11.3.1.6.2.Market Share (%) 2024-2034F
11.3.1.6.3.Y-o-Y Growth (%) 2024-2034F
11.3.2. By Route of Administration
11.3.2.1.Intravenous (IVIG)
11.3.2.1.1. By Value (USD Million) 2024-2034F
11.3.2.1.2.Market Share (%) 2024-2034F
11.3.2.1.3.Y-o-Y Growth (%) 2024-2034F
11.3.2.2. Subcutaneous (SCIg)
11.3.2.2.1.By Value (USD Million) 2024-2034F
11.3.2.2.2. Market Share (%) 2024-2034F
11.3.2.2.3. Y-o-Y Growth (%) 2024-2034F
11.3.2.3. Others
11.3.2.3.1.By Value (USD Million) 2024-2034F
11.3.2.3.2. Market Share (%) 2024-2034F
11.3.2.3.3. Y-o-Y Growth (%) 2024-2034F
11.3.3.By Application
11.3.3.1.Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
11.3.3.1.1. By Value (USD Million) 2024-2034F
11.3.3.1.2.Market Share (%) 2024-2034F
11.3.3.1.3.Y-o-Y Growth (%) 2024-2034F
11.3.3.2. Multifocal Motor Neuropathy (MMN)
11.3.3.2.1.By Value (USD Million) 2024-2034F
11.3.3.2.2. Market Share (%) 2024-2034F
11.3.3.2.3. Y-o-Y Growth (%) 2024-2034F
11.3.3.3. Primary Immunodeficiency Disease (PID)
11.3.3.3.1.By Value (USD Million) 2024-2034F
11.3.3.3.2. Market Share (%) 2024-2034F
11.3.3.3.3. Y-o-Y Growth (%) 2024-2034F
11.3.3.4. Secondary Immunodeficiency Disease (SID)
11.3.3.4.1.By Value (USD Million) 2024-2034F
11.3.3.4.2. Market Share (%) 2024-2034F
11.3.3.4.3. Y-o-Y Growth (%) 2024-2034F
11.3.3.5. Guillain-Barre syndrome
11.3.3.5.1.By Value (USD Million) 2024-2034F
11.3.3.5.2. Market Share (%) 2024-2034F
11.3.3.5.3. Y-o-Y Growth (%) 2024-2034F
11.3.3.6. Immune thrombocytopenic purpura (ITP)
11.3.3.6.1.By Value (USD Million) 2024-2034F
11.3.3.6.2. Market Share (%) 2024-2034F
11.3.3.6.3. Y-o-Y Growth (%) 2024-2034F
11.3.3.7. Others
11.3.3.7.1.By Value (USD Million) 2024-2034F
11.3.3.7.2. Market Share (%) 2024-2034F
11.3.3.7.3. Y-o-Y Growth (%) 2024-2034F
12.North America Immunoglobulins Market Size & Forecast 2024A-2034F
12.1.Overview
12.2. Key Findings
12.3. Market Segmentation
12.3.1. By Product Type
12.3.2.By Route of Administration
12.3.3.By Application
12.4. Country
12.4.1. United States
12.4.2. Canada
13.Europe Immunoglobulins Market Size & Forecast 2024A-2034F
13.1.Overview
13.2. Key Findings
13.3. Market Segmentation
13.3.1.By Product Type
13.3.2.By Route of Administration
13.3.3.By Application
13.4.Country
13.4.1.Germany
13.4.2. United Kingdom
13.4.3. France
13.4.4. Italy
13.4.5. Spain
13.4.6. Russia
13.4.7. Rest of Europe (BENELUX, NORDIC, Hungary, Turkey & Poland)
14.Asia-Pacific Immunoglobulins Market Size & Forecast 2024A-2034F
14.1. Overview
14.2. Key Findings
14.3.Market Segmentation
14.3.1.By Product Type
14.3.2. By Route of Administration
14.3.3. By Application
14.4. Country
14.4.1.India
14.4.2. China
14.4.3. South Korea
14.4.4.Japan
14.4.5.Rest of APAC
15.Middle East and Africa Immunoglobulins Market Size & Forecast 2024A-2034F
15.1.Overview
15.2. Key Findings
15.3. Market Segmentation
15.3.1.By Product Type
15.3.2.By Route of Administration
15.3.3.By Application
15.4.Country
15.4.1. Israel
15.4.2. GCC
15.4.3. North Africa
15.4.4.South Africa
15.4.5. Rest of Middle East and Africa
16. Latin America Immunoglobulins Market Size & Forecast 2024A-2034F
16.1.Overview
16.2. Key Findings
16.3. Market Segmentation
16.3.1. By Product Type
16.3.2.By Route of Administration
16.3.3.By Application
16.4.Country
16.4.1. Mexico
16.4.2. Brazil
16.4.3. Rest of Latin America
17. Competitive Landscape
17.1.Company market share, 2023
17.2. Key player overview
17.3. Key stakeholders
18. Company Profiles
18.1. Grifols
18.1.1.Company Overview
18.1.2.Financial Overview
18.1.3.Key Product; Analysis
18.1.4.Company Assessment
18.1.4.1.Product Portfolio
18.1.4.2.Key Clients
18.1.4.3. Market Share
18.1.4.4. Recent News & Development (Last 3 Yrs.)
18.1.4.5. Executive Team
18.2. CSL Behring
18.3. Takeda Pharmaceutical Company
18.4.Octapharma AG
18.5.BioProduct Laboratory Ltd.
18.6. Kedrion Biopharma
18.7. AbbVie Inc.
18.8.Sanofi
18.9. Emergent BioSolutions
18.10. Polygel Laboratories
18.11.LFB Group
18.12. Shanghai RAAS Blood Products Co., Ltd.
18.13. Hualan Biological Engineering Inc.
18.14. BPL (British Plasma Laboratories)
18.15. Radius Health
18.16. Other Prominent Players
19. Appendix
20.Consultant Recommendation